Skip to content

A Personalized Prevention Program (PPP) Based on the Comprehensive Geriatric Assessment (CGA) for the Prevention of Multidimensional Frailty Related to Non-communicable Chronic Diseases (NCDs) in Older People

A Personalized Prevention Program (PPP) Based on the Comprehensive Geriatric Assessment (CGA) for the Prevention of Multidimensional Frailty Related to Non-communicable Chronic Diseases (NCDs) in Older People: a Practical Approach in Primary Care Setting

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06224556
Acronym
PrimaCare_P3
Enrollment
1216
Registered
2024-01-25
Start date
2024-06-04
Completion date
2025-05-31
Last updated
2024-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Communicable Chronic Diseases, Older People

Keywords

Primary care setting, Comprehensive Geriatric Assessment, Older people, Non-communicable chronic diseases, Personalized Prevention Program, Saliva collection

Brief summary

* Non-Communicable Diseases (NCDs) can accelerated the aging process and increase the frailty condition * The Comprehensive Geriatric Assessment (CGA) is the gold standard in the geriatric clinical context * Recently, in Italy the first Guidelines about the CGA in different settings for older people has been pubblicated * The CGA can identify older people at high risk of frailty who can benefit from a personalized prevention program * No studies has been investigated the effects of a personalized prevention program (PPP) based on the CGA in a primary care setting * The main hypothesis is that the CGA assessment can result in personalized prevention programs for older subjects in primary care settings with an effect in reducing the hospitalization rate and can be related to the biological paramters in NCDs

Detailed description

The main aim of the project is to evaluate in older people the effectiveness of personalized preventive interventions based on the Comprehensive Geriatric Assessment (CGA) in the primary care setting and to explore biological process in Non-Communicable Disases (NCDs). The study involves 1216 subjects enrolled by General Practitioners (GPs) in four different Italian Areas. The GPs involved will be randomised to clusters in a 1:1 ratio, therefore one group of GPs will enrol patients for the Intervention Group and a second group of GPs will include patients for the Control Group. The sample size: A recent Cochrane systematic review reports a significant reduction in the risk of unplanned hospitalisation in community-dwelling elderly persons treated with VMD compared to standard clinical practice (RR= 0.83; CI 95%: 0.70-0.99). Thus, assuming an incidence of unplanned hospitalisations in one year of 38.8% in the group receiving PPP compared to 47.7% in the group randomised to standard care and assuming a power of 80% and a type I error of 5%, a total of 972 participants will be enrolled. Furthermore, assuming a drop-out rate of 20% over the 1-year follow-up period, the final sample will be 1216 participants, 608 in each group 608 subjects will be involved in the intervention group: they will receive the Personalized Prevention Program (PPP) and a saliva sample will be collected. 608 subjects will be involved in the control group according to the normal clinical practice. Both groups will be contacted at 6 and 12 months after the baseline for the follow-up. Statistical analyses: Baseline characteristics will be compared between the group receiving the CGA-based PPP intervention and the control group. Continuous variables will be compared using the t-Student test and categorical variables using the Chi-square test. The cumulative probability of the primary and secondary outcome will be estimated by Kaplan-Meier curve, using the log-rank test to assess differences between the two groups. To assess the risk associated with the primary outcome (rate of unplanned hospitalisation at 12 months) in subjects in the intervention group compared to subjects in standard care, the Hazard Ratio (HR) will be estimated by fitting a Cox model, after testing for proportional hazards. Similarly, the risk of secondary outcomes will be estimated.

Interventions

COMBINATION_PRODUCTBrief-MPI assessment (based on the Comprehensive Geriatric Assessment); Personalized Prevention Program

Patients will be evaluated at baseline and at 6 and 12 months after the baseline through the CGA, the Resilience Scale (RS-14 items) and the Psychological General Wellbeing Index short form. The prevention program will be received at the baseline, so at the two follow-ups patients wiil asked the adherence to it and the level of satisfaction (Client Satisfaction Questionnaire - 8 items). Saliva sample will be collected and analyzed.

Sponsors

Alberto Pilotto
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Caregiver)

Masking description

The General Practitioners (GPs) involved will be randomised in clusters in a 1:1 ratio, therefore one group of GPs will enrol patients for the Intervention Group and a second group of GPs will include patients for the Control Group. Therefore, the role of GPs are masked.

Intervention model description

The Intervention Group will receive the Personlized Prevention Program (PPP) be evaluated by a Comprehensive Geriatric Assessment thanks to the Multidimensional Prognostic Index (MPI) questionnaire.

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 65 years old and over * At least 1 non-communicable chronic disease * Signed informed consent

Exclusion criteria

* not willing in partecipating in the study and no signed informed consent * \<65 years old * without non-communicable chronic diseases

Design outcomes

Primary

MeasureTime frameDescription
Hospitalization rate12 monthsUnplanned hospitalization rate

Secondary

MeasureTime frameDescription
Composed outcome6 and 12 monthsComposed outcome including: emergency access rate, hospitalization and institutionalization rates at 6 and 12 months after the baseline.
Number of unplanned General Practitioners visits12 monthsUnplanned GPs visits
Mortality rate6 and 12 monthsmortality rate at 6 and 12 months

Other

MeasureTime frameDescription
NAD/NADH in the Intervention GroupAfter the saliva collection at the baselineSaliva analyses for theNAD/NADH parameter
TBARS in the Intervention GroupAfter the saliva collection at the baselineSaliva analyses for the TBARS parameter
TNF-alfa in the Intervention GroupAfter the saliva collection at the baselineSaliva analyses for theTNF-alfa parameter
Adherence at the PPP6 and 12 monthsAdherence at the Personalized Prevention Program by the Intervention Group
IL-6 in the Intervention GroupAfter the saliva collection at the baselineSaliva analyses for the IL-6 parameter
IL-8 in the Intervention GroupAfter the saliva collection at the baselineSaliva analyses for the IL-8 parameter
Microbioma saliva analysis in a sub-group of the Intervention GroupAfter the saliva collection at the baselineThe microbioma saliva sample will be analysed in 210 subjects from the Intervention Group through the DNA GENOTEK OME-505 Omnigene Oral Collection Kits for Nucleic Acid Saliva
IL-1b in the Intervention GroupAfter the saliva collection at the baselineSaliva analyses for the IL-1b parameter
Psychological Well-beingBaseline, 6 and 12 monthsPsychological well-being assessed to the Intervention Group
ResilienceBaseline, 6 and 12 monthsResilience outcome evaluated in the Intervention Group
Lactate in the Intervention GroupAfter the saliva collection at the baselineSaliva analyses for the Lactate parameter

Countries

Italy

Contacts

Primary ContactAlberto Pilotto
alberto.pilotto@galliera.it0039 0105634467
Backup ContactMarina Barbagelata
marina.barbagelata@galliera.it

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026